Pharmacokinetic studies rely on blood sampling at times relative to predefined dosing
intervals. Intensive sampling is often done under direct observation of dose taking, which …

Lopinavir is one of the most-widely used protease inhibitors in the treatment of HIV-1
infected patients. Concentration-effect relationships have been described for both antiviral …

Population pharmacokinetics has been an important technique used to explore and define
relevant sources of variation in drug exposure and response in patient populations. This has …

Background: A relationship between plasma concentrations and viral suppression in
patients receiving lopinavir (LPV)/ritonavir (RTV) has been observed. Therefore, it is …

Aims To develop a population pharmacokinetic model for lopinavir in combination with
ritonavir, in which the interaction between both drugs was characterized, and in which …

Nonlinear mixed-effects modeling was applied to explore the relationship between lopinavir
and ritonavir concentrations over 72 h following drug cessation and also to assess other …

We developed a novel HIV-1 dynamic model with consideration of pharmacokinetics, drug
adherence and drug susceptibility to link plasma drug concentration to the long-term …

Objective This work aimed at building a population pharmacokinetic (PK) model for
lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and …

Background: Lopinavir is a protease inhibitor indicated for the treatment of HIV infection. It is
coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After …

Aims The aim of this study was to develop and validate a population pharmacokinetic model
of ritonavir, used as an antiviral agent or as a booster, in a large patient population and to …